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Abstract 
GENOMIC STRUCTURAL EQUATION MODELING: A NOVEL METHOD 
USED TO UNDERSTAND THE SHARED GENETIC BASIS OF MENTAL  
HEALTH DISORDERS 
Andrew David Grotzinger, Ph.D. 
The University of Texas at Austin, 2021 
Co-supervisors: Elliot M. Tucker-Drob, Kathryn Paige Harden 
Methods for using genome-wide association studies (GWAS) to estimate genetic 
correlations between pairwise combinations of traits have produced “atlases” of genetic 
architecture. Genetic atlases reveal pervasive pleiotropy, and genome-wide significant 
loci are often shared across a wide variety of phenotypes. The present dissertation 
consists of three main sections, with the overarching goal of developing and applying 
multivariate methods that allow greater understanding of psychiatric, genetic atlases. 
First, Genomic Structural Equation Modeling (Genomic SEM) is tested and validated. 
Using formal methods for modeling covariance structure, Genomic SEM synthesizes 
genetic correlations and SNP-heritabilities inferred from GWAS summary statistics of 
individual traits from samples with varying and unknown degrees of overlap. Second, 
Stratified Genomic SEM is developed as an extension that allows for modeling genetic 
covariance stratified across biologically meaningful classes of genes. These stratifications 
can include classes of genes expressed during certain developmental epochs (e.g., genes 
expressed prenatally), tissues (e.g., genes expressed in the hippocampus), and cell types 
(e.g., pyramidal neurons). Third, Genomic SEM and Stratified Genomic SEM are applied 
to provide a greater understanding of shared genetic risk across 11 major classes of 
iv 
 v 
psychiatric traits. These results provide insight into genetic risk sharing across the 
diagnostic spectrum at the genome-wide level, for classes of genes, and for individual 
genetic loci.  
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Approximately half of individuals with a mental disorder concurrently meet criteria for 
another disorder (Kessler, Chiu, Demler, & Walters, 2005), and ~41% of individuals will meet 
criteria for four or more disorders in their lifetime (Caspi & Moffitt, 2018). In addition, offspring 
of parents with mental illness are at higher risk for developing any mental disorder, and not just 
the specific parental disorder (Dean et al., 2018; Martel et al., 2017; McLaughlin et al., 2012). 
Bivariate genomic methods (e.g., GCTA & LD-score Regression) consistently reveal high levels 
of genetic covariance across a diverse range of psychiatric disorders (Bulik-Sullivan et al., 2015; 
Selzam, Coleman, Caspi, Moffitt, & Plomin, 2018). Thus, a substantive reason for non-specific 
familial risk, and pervasive psychiatric comorbidity more generally, appears to be widespread 
statistical pleiotropy.  
In addition to phenotypic patterns of comorbidity and evidence for genetic overlap, the 
extant literature points to a number of overlapping biological mechanisms across psychiatric 
traits. With respect to neurotransmitters, dysregulations in the glutamatergic system are widely 
cited for attention-deficit/hyperactivity disorder (ADHD; e.g., Elia et al., 2011), bipolar disorder 
(e.g., Forstner et al., 2015), and schizophrenia (e.g., Hu et al., 2015). GABAergic abnormalities 
have been identified across an even wider range of disorders, including: schizophrenia 
(Guillozet-Bongaarts et al., 2014), bipolar disorder (Fatemi et al., 2013), major depressive 
disorder (MDD; Gao et al., 2013), ADHD (Fatemi et al., 2013), anxiety disorders (Mohler, 
2012), and autism spectrum disorder (Fatemi et al., 2010). Structural abnormalities are also 
commonly reported across all disorders, but grey matter loss specific to the hippocampus may 




MDD (Schmaal et al., 2016). Thus, genetic and, more generally, biologically informed research 
clearly points to a need for multivariate methods that can be used to more systematically 
investigate overlapping genetic pathways of psychiatric risk.  
The current dissertation consists of three main parts. First, I develop and validate a novel 
method, Genomic Structural Equation Modeling (Genomic SEM; Grotzinger et al., 2019), that 
allows genetic covariance matrices produced from GWAS summary statistics to be formally 
modeled. In Chapter 2, I validate Stratified Genomic SEM, an extension of the Genomic SEM 
framework that allows genetic covariance to be modeled within biologically meaningful 
categories, allowing us to examine genetic enrichment for overarching factors of psychiatric 
liability. These biological categories are constructed based on collateral information from gene 
expression methods (e.g., RNA-Seq), and include classes of genes that map onto the overlapping 
biological mechanisms noted in the prior paragraph (e.g., genes expressed in the hippocampus). 
While independent studies that include individual diagnoses repeatedly point to the convergence 
of biological risk factors, Stratified Genomic SEM allows this risk sharing to best tested for the 
first time across an encompassing range of the diagnostic spectrum. In Chapter 3, I pair Genomic 
SEM with the most up-to-date summary statistics across 11 classes of major psychiatric 
disorders (average total sample size = 154,923 participants), to systematically evaluate 
competing structural models. I subsequently apply Stratified Genomic SEM to identify genetic 
enrichment of psychiatric factors within biologically meaningful categories of genes. Finally, I 
utilize multivariate GWAS within Genomic SEM to identify risk conferring loci across the 




pathways, and individual genetic variants, to offer critical and comprehensive insight into the 
























Chapter 1: Validation of Genomic SEM1 
INTRODUCTION 
Genome-wide association studies (GWASs) are rapidly identifying loci affecting multiple 
social, behavioral, and psychiatric phenotypes (Lee et al., 2013; Bush, Oetjens, & Crawford, 
2016). Moreover, using cross-trait versions of methods such as genomic-relatedness-based 
restricted maximum-likelihood (GREML; Yang, Lee, Goddard, & Visscher, 2011) and LD-score 
regression (LDSC; Bulik-Sullivan et al., 2015) researchers have identified genetic correlations 
between diverse traits, such as age of first birth and risk of smoking (Barban et al., 2016),  
insomnia and psychiatric traits (e.g., schizophrenia; Jansen et al., 2018), and major depressive 
disorder and number of children (Wray et al., 2018). In fact, widespread pleiotropy appears to be 
the rule rather than the exception across phenotypes. Although these findings are currently 
suggestive of constellations of phenotypes affected by shared sources of genetic liability, 
existing methods do not permit the causes of the observed genetic correlations to be investigated 
systematically.  
As part of this dissertation, I have worked actively with my supervisors to create and 
validate Genomic SEM, a novel method for modeling the multivariate genetic architecture of 
constellations of traits and incorporating genetic covariance structure into multivariate GWAS 
discovery. Genomic SEM is a flexible framework for formally modeling the genetic covariance 
 
1 Results reported in the first chapter appear in the published work (Grotzinger et al., 2019). My 
contributions to this work included the conceptualization, analyses, and write-up of the results. 
Grotzinger, A. D., Rhemtulla, M., de Vlaming, R., Ritchie, S. J., Mallard, T. T., Hill, W. D., ... & Tucker-Drob, E. 
M. (2019). Genomic structural equation modelling provides insights into the multivariate genetic architecture of 





structure of complex traits using GWAS summary statistics from samples of varying and 
potentially unknown degrees of overlap, in contrast to existing methods that model phenotypic 
covariance structure (Verhulst, Maes, & Neale, 2017), with very specific applications (Beaumont 
et al., 2018), using raw data. Moreover, Genomic SEM allows for the specification and 
comparison of a range of different hypothesized multivariate genetic architectures, which 
improves upon existing approaches for combining information across genetically correlated traits 
to aid in discovery (Turley et al., 2018).  
Genomic SEM is a Two-Stage Structural Equation Modeling approach (Cheung, 2015; 
Savalei & Bentler, 2009; Yuan & Bentler, 2000). In Stage 1, the empirical genetic covariance 
matrix and its associated sampling covariance matrix are estimated. The diagonal elements of the 
sampling covariance matrix are squared standard errors (SEs). The off-diagonal elements index 
the extent to which sampling errors of the estimates are associated, as may be the case when 
there is sample overlap across GWAS. In principle, these matrices may be obtained using a 
variety of methods for estimating SNP heritability, their genetic covariance, and their SEs. Here 
we use a novel, multivariate version of LDSC that accounts for potentially unknown degrees of 
sample overlap by populating the off-diagonal elements of the sampling covariance matrix. The 
same strengths, as well as assumptions and limitations, that are known to apply to LDSC (de 
Vlaming, Johannesson, Magnusson, Ikram, & Visscher, 2017; Lee & Chow, 2017) apply to its 
extension used here and to Genomic SEM. In Stage 2, a SEM is estimated by minimizing the 
discrepancy between the model-implied genetic covariance matrix and the empirical covariance 
matrix obtained in the previous stage.  




In Stage 1, the empirical genetic covariance matrix (SLDSC) and its associated sampling 
covariance matrix (VSLDSC) are estimated using our multivariable extension of LDSC. SLDSC is a 
k ´ ksymmetric matrix with SNP heritabilities on the diagonal and genetic covariances (σgi,gj) 
between phenotypes i and j off the diagonal. The genetic covariance between phenotypes i and j 
can be computed as the genetic correlation scaled relative to the total genetic variance of each of 
the two contributing phenotypes (themselves scaled to unit variances), 2 2
, ,gi gj gi gj i jr h h  =  . 
Thus, the genetic covariance matrix of order k has k* = k k +1( ) / 2  nonredundant elements. It 
can be written as:  
    
To produce unbiased SE estimates and test statistics, we require the asymptotic sampling 
covariance matrix, VSLDSC, of the LDSC estimates that is composed of all nonredundant elements 
in the SLDSC  matrix. Thus, it is a symmetric matrix of order k*, with k
* k* +1( ) / 2  nonredundant 
elements. The diagonal elements of VSLDSC are sampling variances, that is, squared SEs of the 
elements in SLDSC. The off-diagonal elements of VSLDSC are sampling covariances that indicate the 
extent to which the sampling distributions of the variance and covariance estimates in SLDSC 
covary with one another, as would be expected when there is overlap among the samples from 




 The diagonal elements of VSLDSC are estimated using a jackknife resampling procedure in 
the bivariate version of LDSC that is currently available by its original developers (Bulik-
Sullivan et al., 2015). The LDSC function introduced in the software package expands the 
jackknife procedure to the multivariable context in order to produce sampling covariances 
(which index dependencies among estimation errors) among the elements of SLDSC, needed to 
populate the off-diagonal elements of VSLDSC.  
Incorporation of Individual SNP Effects 
Several steps are needed to incorporate individual SNP effects into Genomic SEM. The 
first step requires that the inputted genetic covariance matrix be expanded to include covariances 
between the SNP and each of the phenotypes, g1 through gk, by appending a vector of SNP-





The sampling covariance matrix, VSFull, associated with this expanded SFull covariance matrix 
includes a number of components. One block of this VSFull matrix, VSLDSC, contains the sampling 
variances and sampling covariances of the latent genetic variances (SNP heritabilities) and 
genetic covariances, which are obtained from the multivariable LDSC approach introduced 
above. A second block of the VSFull matrix, VSSNP, is composed of the sampling covariance matrix 
of the SNP effects on the phenotypes. The SNP variance (derived from reference panel data) is 
treated as fixed, and its sampling variance and sampling covariance with all other terms are fixed 
to 0 (or to a very small value to facilitate computational tractability). The sampling covariances 
of the SNP-genotype covariances with one another are obtained using cross-trait LDSC 
intercepts (which represent sampling correlations weighted by sample overlap) after being 
rescaled relative to the sampling variances of the respective SNP-genotype covariances 
(Baselmans et al., 2017; Turley et al., 2018). A final block of the VSFull matrix represents the 
sampling covariance of the SNP-genotype covariances with the genetic variances and genetic 
covariances. These are fixed to 0, as sampling variation of the SNP-genotype covariance is 
expected to be independent of the test statistics of all LD blocks except the one it occupies. 
Because the sampling variance of the heritabilities and genetic correlations derive from sampling 




















Stage 2 Estimation 
In Stage 2, the genetic covariance matrix (S) obtained in the previous stage, is used to 
estimate the parameters in a SEM. The fit function minimized in the diagonally weighted version 
of WLS estimation that is standard in the Genomic SEM software package is the following:  
 ( ) ( )( ) ( )( )1WLS SF s D s    
−= − − , 
where S and Σ(θ) have been half-vectorized to produce s and σ(θ) respectively, and DS is VS with 
its off-diagonal elements set to 0. We choose the diagonally weighted version of WLS because it 
is more tractable to implement for large (highly multivariate) matrices and is more stable than 
fully weighted WLS in finite samples (Flora & Curran, 2004; Savalei, 2014).  
The WLS fit function will produce consistent estimates of the model parameters when the 
model is true (Savalei, 2014). However, the “naïve” SEs and fit statistic produced in Stage 2 
estimation will be incorrect, because the estimator does not use the full VS matrix in estimation. 
Thus, robust corrections must be applied to produce consistent estimates of SEs and test 
statistics. The correct sampling covariance matrix of the Stage Two, Genomic SEM parameter 
estimates (i.e., V ) can be obtained using a sandwich correction (Savalei, 2014; Savalei & 
Bentler, 2009): 
( ) ( )
1 1
1 1 1 1ˆ ˆ ˆ ˆ ˆ ˆ
SV V
− −













is the matrix of model derivatives evaluated at the parameter estimates, and 
G  is the naïve Stage 2 weight matrix.  
QSNP Test of Heterogeneity 
As part of Genomic SEM, an index is provided that quantifies the extent to which an 
observed vector—consisting of univariate regression effects of a given SNP on each of the 
phenotypes—can be explained by a common pathway model that assumes that the effects on the 
phenotypes are entirely mediated by the common genetic factor(s). In other words, this index 
enables the identification of loci that do and do not operate on the individual phenotypes 
exclusively by way of their associations with the common factor(s). Because of its intuitive and 
mathematical similarity to the meta-analytic Q-statistic used in standard meta-analyses to index 
heterogeneity of effect sizes (Huedo-Medina, Sánchez-Meca, Marín-Martínez, & Botella, 2006) 
we label this heterogeneity statistic, QSNP. QSNP is a 2-distributed test statistic with larger values 
indexing a violation of the null hypothesis that the SNP acts entirely through the common 
factor(s).  
QSNP is calculated using a two-step procedure. In Step 1, a common pathway model is fit 
in which both factor loadings, the SNP effect on the common factor(s), and the residual 
variances of the common and unique factors are freely estimated (with one factor loading fixed 
to unity for factor identification and scaling). No paths representing direct effects of the SNP on 
the genetic components of the individual phenotypes are estimated. In Step 2, a common plus 




common factor are fixed to the values estimated in Step 1, and direct effects of the SNP on 
individual indicators and the residual variances of each indicator are freely estimated.  
METHOD 
Standardization and Scaling of Summary Statistics for Multivariate GWAS 
Typically, GWAS summary statistics for quantitative phenotypes are not reported in 
terms of covariances but as ordinary least squared (OLS) unstandardized regression coefficients, 
with the phenotypes standardized prior to analyses (i.e., the coefficients are standardized with 
respect to the outcome, but not the predictor). In order to transform these partially standardized 
regression coefficient (bSNP,P) of a SNP effect on phenotype P to a covariance, we multiply by the 
variance of scores on the SNP. The variance (s
SNP
2 ) of scores (0, 1, 2) of a biallelic autosomal 
SNP is estimated as 2pq, assuming Hardy-Weinberg-Equilibrium, where p = the minor allele 
frequency (MAF) and q = 1-MAF, with the MAF typically obtained from a reference sample. As 
the latent genetic factors estimated in LDSC are scaled relative to unit-variance scaled 
phenotypes (by virtue of the SNP heritability estimates being placed on the diagonal of S), no 
further scaling is needed to transform this SNP-phenotype covariance into a SNP-genotype 
covariance. 
When OLS regression coefficients and standard errors are provided from an analysis in 
which the phenotype has not been standardized prior to analyses, or only Z statistics or p-values 
(for which Z statistics can be readily obtained) are provided, the partially standardized regression 

































b is equal to the regression coefficient for the OLS GWAS of the 
unstandardized phenotype. These derived partially standardized coefficients are then transformed 
into covariances by multiplying by the variance of scores on the SNP, as per above. 
When the GWAS summary statistics are reported for logistic regressions of liabilities for 
categorical outcomes (e.g. case/control status) on the SNP, the logistic regression coefficients 
can be transformed into covariances as above, by multiplying by the SNP variances. However, it 
is appropriate to further transform the coefficients and their SEs such that they are scaled relative 








as a logistic regression model implies a residual variance of 
p 2
3
. If GWAS summary statistics 
are reported for odds ratios (ORs), they can be transformed to logistic regression coefficients by 
taking their natural logarithm. Standard errors for the logistic regression coefficient are obtained 
as SEOR/OR. The derived logistic coefficients and their SEs should further be transformed such 
that they are scaled relative to unit-variance scaled phenotypes, as per above. Note that when the 
outcomes are categorical, the liability scale heritabilities and genetic covariances from 
multivariable LDSC (and not what are referred to as the “observed scale” heritabilities and 
genetic covariances) should be used to populate the S matrix. This has the desirable property of 
both modeling the continuous scale of risk in the population and providing estimates that are 
independent of the observed prevalence of the categorical outcomes. 
On occasion, summary statistics will be provided from OLS GWASs of categorical 




probability model, as it (incorrectly) assumes that the association between the predictor and the 
probability of being in the comparison (e.g. case) group relative to the reference (e.g. control) 
group is linear. Parameters from the linear probability model are dependent not only on the 
strength of the association between the SNP and the continuous underlying liability, but also on 
the MAF and the proportion of comparison group members (cases) in the sample. Thus, 
parameters from the linear probability model cannot be used directly in Genomic SEM. 
However, particularly in the case of complex traits, for which the effect sizes for individual 
SNPs are small, results from the linear probability model can be used to very closely 
approximate logistic regression coefficients and SEs that are amenable for use in Genomic SEM 




























b is equal to the 
regression coefficient from the linear probability model, blogit
SNP,P
* is the expected logistic 
regression coefficient that is derived from the linear probability model results, v is equal to the 
proportion of cases in the sample, and s
SNP
2  is the variance of the SNP, computed from its MAF 
obtained from a reference sample, as per above. To scale the derived logistic coefficient such 








, as is done in the case of logistic regression (case/control) effects 
described above.   




 Model 2 is an index of exact fit of a SEM. It indexes whether the model-implied genetic 
covariance matrix, Σ(θ), differs from the empirical genetic covariance matrix, S. Model 2 can 
also be used as a relative fit index for comparing nested models. Conventional SEM approaches 
to indexing model 2 are based on formulas that directly incorporate N. Because there is not an N 
that directly corresponds to the genetic covariance matrix that is modelled by Genomic SEM in 
the same way that N typically corresponds to an observed covariance matrix, a formula was 
derived for estimating model 2 that does not require N, but instead incorporates the sampling 
covariance matrix of the model residuals. This is done in two steps. In Step 1, the proposed 
model (e.g., a common factor model) is estimated. In Step 2, all of the Step 1 estimates are fixed, 
and the residual covariances and residual variances of the indicators are freely estimated. 
Residual variances are estimated in Step 2 by estimating the variances of k residual factors 
defined by the indicators. This provides an estimate of the discrepancy between the model 
implied and observed covariance matrices, R = S - S q( ), along with the sampling covariance 
matrix (VR) of R. While the discrepancy between model implied and observed covariance 
matrices can be computed simply by deriving covariance expectations from the Step 1 model and 
subtracting the observed covariance matrix, such an approach would not provide the 
corresponding VR matrix necessary for the calculations below. The VR matrix is expected to be 
positive semidefinite and, consequently, have no negative eigenvalues. Therefore, the VR matrix 
has the following eigendecomposition:  








where P1 is a matrix of principal components (eigenvectors) of VR, and 𝛦 is a corresponding 
diagonal matrix consisting of non-zero eigenvalues. P0 reflects the null space of VR. Projecting 
Ri—a vector of residual covariances estimated from the Step 2 Model—onto P1 and adjusting for 
corresponding eigenvalues, we have that: 
𝐸
−1
   2𝑃1






This equation produces a test statistic that is 2 distributed with degrees of freedom equal to the 
difference between the number of nonredundant elements (k*) in the empirical covariance matrix 
(S) and the number of freely estimated parameters in the proposed model, as would be the case in 
any regular SEM.  
The Comparative Fit Index (CFI) is a test of approximate model fit. CFI indexes the 
extent to which the proposed model fits better than a model that allows all phenotypes to be 
heritable, but assumes that they are genetically uncorrelated. The 2 statistic can be used to 
calculate CFI by calculating a second 2 statistic for a so-called independence model, i.e. a model 
that estimates genetic variances of all phenotypes but assumes all genetic covariances to be zero, 
such that ∑(θ) is diagonal. CFI is calculated using the formula below (Kenny, 2014), with f = 2 
– degrees of freedom: 
 f(Independence Model) – f(Proposed Model) 




For the 2 of the independence model, a model is estimated in Step 1 that includes only 
the variance of the indicators and no common factor. In Step 2, these variances are fixed and the 
covariances among the indicators and variances of k residual factors defined by the indicators are 
estimated and used to populate the same equation above used to calculate the proposed model 2. 
CFI values theoretically range from 0 to 1, with higher values indicating good fit. CFI values of 
.90 and above are typically considered acceptable fit, and values of .95 and above are typically 
considered good model fit (Kaplan, 2008). When the empirical covariance matrix contains a 
large number of cells that are very close to 0, CFI values may be low, even when such cells are 
approximated well by the model. 
Akaike Information Criterion (AIC) is a relative fit index that balances fit with 
parsimony, and can be used to compare models regardless of whether they are nested. AIC is 
calculated as: 
AIC = 2 + 2 × fp, 
where fp is the number of free parameters in the model (Tanaka, 1993). Lower AIC values are 
considered superior. 
Standardized Room Mean Square Residual (SRMR) is an index of approximate model fit 
that is calculated as the standardized root mean squared difference between the model-implied 
and observed correlations in Σ(θ) and S, respectively (Hu & Bentler, 1999). Higher SRMR 
values indicate a larger discrepancy between Σ(θ) and S. It is positively-biased, with larger bias 
resulting when the contributing univariate GWAS samples are lower powered. SRMR values 
below .10 indicate acceptable fit, values less than .05 indicate good fit, and a value of 0 indicates 




Simulation of Factor Structure 
In order to evaluate the ability of Genomic SEM to capture the genetic factor structure in 
the generating population, the GCTA package (Yang et al., 2011) was used to generate 100 sets 
of 6 independent, 100% heritable phenotypes (“orthogonal genotypes”) to pair with genotypic 
data for 39,909 randomly selected, unrelated individuals of European descent from UKB data for 
the 1,209,498 SNPs present in HapMap3. The generating list of causal SNPs was set to 10,000 
for all 600 genotypes, with the specific list of causal variants sampled with replacement from the 
1,209,498 SNPs. One of the six orthogonal genotypes per set was designated an index of the 
general genetic factor and the remaining five were designated indices of domain-specific genetic 
factors. All of these orthogonal genotypes were scaled to M=0, SD=1. Five new correlated 
genotypes were then constructed, each as the weighted linear combination of the general genetic 
factor and one domain-specific genetic factor. Weights for contribution of the general genetic 
factor were λFg,k =.70, .60, .50, .40, and .30, for correlated genotypes 1-5, respectively. Weights 
for the domain-specific factors were √(1 − λ𝐹𝑔,𝑘
2 ). Phenotypes were then each constructed as 
the weighted linear combination of one of the correlated genotypes and domain-specific 
environmental factors (randomly sampled from a normal distribution with M=0, SD=1). 
Heritabilities for phenotypes 1-5 were set to ℎ𝑘
2=35%, 40%, 50%, 60%, and 70%, respectively, 
such that the weights for the genotypes were √ℎ𝑘
2 and the weights for the environmental factors 
were √(1 − ℎ𝑘
2). We chose these figures to stabilize the properties of the distributions across 
simulations at 100 replications with N~39K each. We expect that with lower SNP h2’s, the same 




phenotypes) was then analyzed as a univariate GWAS in PLINK (Purcell et al., 2007) to produce 
univariate GWAS summary statistics. Our multivariable LDSC function was then used to 
construct 100 sets of 5×5 genetic covariance matrices (S) and associated sampling covariance 
matrices (VS), and Genomic SEM was used to fit a one factor model to each set.  
Simulation of Partial Sample Overlap 
In order to examine the effect of sample overlap on estimates obtained from Genomic 
SEM, the GCTA package (Yang et al., 2011) was used to generate a 50% heritable, quantitative 
phenotype with 30,000 causal SNPs. The phenotype was paired with genetic data from 100,000 
randomly selected, unrelated individuals of European descent from UKB data for 1,209,498 
HapMap3 SNPs. Three sets of 60,000 participants each were created using this same phenotype, 
with 40,000 participants overlapping across all three identical phenotypes and 20,000 
participants unique to each phenotype (i.e., 100,000 total participants). These three subsamples 
were individually analyzed in PLINK (Purcell et al., 2007) to produce univariate GWAS 
summary statistics. The multivariable LDSC function was then used to construct the genetic 
covariance and sampling covariance matrix using the three sets of summary statistics, and 
Genomic SEM was used to fit a one factor model with the SNP predicting the common factor. 
Two key pieces were verified at this stage. First, we confirmed that the standardized factor 
loadings on the common factor were 1 for the identical phenotypes. Second, we verified that the 
bivariate LD-score intercepts that are used to account for sample overlap in the sampling 
covariance matrix were as expected. The equation for the LD-score bivariate intercept is: 
Ns/√(N1N2), where Ns = sample overlap,  = the phenotypic correlation, N1 = sample size of 




which is as expected given sample overlap of 40,000, a phenotypic correlation of 1, and sample 
sizes of 60,000 (i.e., 40,000*1/√(60,000*60,000) = .67). Finally, estimates from this multivariate 
GWAS were compared to estimates from the univariate GWAS in PLINK for the full set of 
100,000 participants. 
RESULTS 
Validation of Summary-Based Model Fit Statistics via Simulation 
A generating population with a common factor model defined by four, five, or six 
indicators was used to examine the null distribution of the newly derived 2 test statistic using a 
set of 1,000 simulations per model. These simulations did not include individual genotypes, and 
were simulated solely based on a generating factor structure. For the six indicator models the 
standardized factor loadings in the generating population were .42, .64, .22, .59, .19, and .64. The 
four and five indicator models specified the same factor loadings, excluding the last, or last two 
loadings, respectively. Results indicated that the two-step procedure described above produced a 
test statistic equivalent to the 2 statistic calculated by lavaan from the raw data (r > .99). For a 
2
 
distributed test-statistic, the mean of the null sampling distribution should match the df of the 
test. As expected, the distribution of the test-statistic conformed to a 2 distribution with an 
average approaching the df. Calculated CFI values were also highly consistent (r > .99) with 
those observed using the CFI statistic provided by lavaan when using raw data. Calculated AIC 
values were not contrasted with those obtained using the lavaan package in R in the simulations 
below as the software uses a formula that includes a log-likelihood estimate contingent on the 
provided sample size.   




To verify that the null distribution for QSNP is 2 distributed, a set of simulations specified 
a generating population in which the direct effects of the SNP on the indicators were entirely 
mediated through the common factor. Each simulation included 1,000 datasets, with N = 100,000 
completely overlapping participants per dataset. We examined three models with F = 1 factor, 
and k = 4, 5, or 6 phenotypes. Using a genome-wide significance threshold, in all cases the false 
discovery rate for QSNP was 0, and the power to detect a SNP effect on the common factor was 1. 
Mean estimates of QSNP were approximately equal to the df of the corresponding model. Figure 1 












Figure 1. Null distributions of QSNP for 1,000 simulations Per Model. Red lines for all panels 
depict the chi-square distribution with the relevant df. The top, middle, and bottom panels depict 
the sampling distributions for 3, 4, and 5 df, respectively.   
 
Recovery of Model Population Parameters 
We performed 100 runs of Genomic SEM on raw individual-level genotype data for 
which we simulated multivariate phenotypic data to conform to a single genetic factor model (a 
latent trait that partially causes 5 observed outcomes). Across the 100 simulations Genomic SEM 























































































































Figure 2. Genomic SEM Simulation Results. Results from 100 runs of Genomic SEM using 
data simulated at the level of the SNPs. Results are presented for unstandardized (panel a) and 
standardized (panel b) estimates. Parameters outside of the parentheses indicate those provided 
in the generating population. In parentheses, we provide the average point estimate and the ratio 
of the mean SE estimate across the 100 runs over the empirical SE (calculated as the standard 
deviation of the parameter estimates across the 100 runs). The ratio of mean and empirical SEs 
was close to 1 in all cases, although slightly above 1 (i.e., conservative) for standardized 
estimates of residual variance. These SE estimates are expected to be upwardly biased in the 






















































































































































WLS:	Chi-Square		 LS:	AI 		 WLS:	CFI		
ML:	Chi-Square		 L:	AIC		 ML:	CFI		
Model SEs also closely matched the standard deviations of parameter estimates. We also 
compared fit statistics (CFI, AIC, and model 2) for the correctly specified common factor model 
and two deliberately misspecified models: (i) a model in which all indicators were constrained to 
have the same factor loading, and (ii) a model for which the loading of the third indicator was set 
to 0. As expected, results indicated that the common factor model matching the generating 











Figure 3. odel Fit Indices from Genomic EM Simulations. Model fit indices were 
compared across the 100 runs of Genomic SEM using simulated data. Depicted in blue are model 
fit indices for runs specified to match the generating population (i.e., one common factor with 
freely estimated factor loadings). Depicted in green are indices for models specified to have 
equal factor loadings across all indicators. Depicted in red are indices for a model in which the 
third indicator loading was fixed to 0. Indices favored the model that matched the generating 
population for model chi-square, AIC, and CFI in 100% of cases, with the exception that 99 
models favored the matching model for AIC.  
 
Simulation of Sample Overlap 
One major benefit of Genomic SEM is that summary statistics can be used from samples 
with unknown degrees of sample overlap. We performed a simulation in order to verify that the 
inclusion of data from overlapping samples does not bias Genomic SEM parameter estimates or 
their standard errors. We simulated data for a single quantitative phenotype in 100,000 




(with ~66% pairwise overlap between the subsamples). We submitted each of the three 
subsamples to an independent GWAS, and used the three resulting sets of summary statistics as 
input for a Genomic SEM model, in which we specified the phenotype from each individual set 
of summary statistics as a different indicator of a common factor, onto which a SNP effect was 
specified. If sample overlap is not appropriately accounted for, data are incorrectly treated as 
deriving from 180,000 participants (as opposed to 100,000 total participants), and we would 
expect the Z-statistics for the SNP effects to be upwardly biased relative to those from a 
univariate GWAS applied directly to the single phenotype in the 100,000 participants. As 
expected, we observed no such bias. A linear regression of estimates from the Genomic SEM 
model from the three overlapping samples of 60,000 participants each predicting univariate 
GWAS Z statistics in the complete sample of 100,000 participants revealed near perfect 
correspondence (unstandardized slope = 1.003, intercept = -.003). 
DISCUSSION 
Applications of genome-wide methods to data from large scale population-based samples 
have uncovered clear evidence of pervasive shared genetic architecture across social, behavioral, 
and psychiatric traits. We created the Genomic SEM framework for modeling the multivariate 
genetic architecture of constellations of genetically correlated traits and incorporating genetic 
covariance structure into multivariate GWAS discovery. In contrast to existing methods 
(Verhulst et al., 2017) that model phenotypic, rather than genetic covariance structure, and rely 
on raw data, Genomic SEM employs summary GWAS data to model genetic covariance 




of sample overlap, and allows for flexible specification of covariance structure, such that several 
broad classes of structured covariance models can be applied.  
The Genomic SEM approach shares benefits of some existing approaches (Turley et al., 
2018) for boosting power by combining information across genetically correlated phenotypes. 
However, Genomic SEM uniquely allows one to compare different hypothesized genetic 
covariance architectures and to incorporate such architectures into multivariate discovery. 
Importantly, shared genetic liabilities across phenotypes can be explicitly modeled as factors that 
may be treated as broad genetic risk factors with equally broad downstream consequences. 
Multivariate genetic methods have existed for decades in the twin literature, with Martin and 
Eaves (1977) providing a framework for fitting structural equation models of genetic and 
environmental variance components in multivariate twin data. Genomic SEM can be used to 
reproduce multivariate genetic models from the existing twin literature using GWAS summary 
data from unrelated individuals. Moreover, Genomic SEM offers new promise as a method that 
allows for the estimation and modeling of genetic covariance even among phenotypes for which 
phenotypic covariance cannot be estimated.  
Genomic SEM is not the only method for multivariate GWAS. Other methods, such as 
MTAG (Turley et al., 2018), SHom/SHet (Zhu et al., 2015), metaUSTAT (Ray & Boehnke, 
2018), min-P (O’Reilly et al., 2012), and TATES (Van der Sluis, Posthuma, & Dolan, 2013) 
allow researchers to perform multivariate meta-analyses based solely on summary data. The 
methods can generally be divided into 2 distinct classes: methods which aggregate test statistics 
or effect sizes based on a model (Genomic SEM, SHom and MTAG) and those which efficiently 




and SHet). As we show with respect to MTAG, some models can be fit in the context of 
Genomic SEM. It is also conceivable that the approach of efficiently selecting the minimum p-
value from a set of analyses while maintaining proper Type-I error control could be integrated 
within Genomic SEM. For instance, whereas TATES is currently applied to select the minimum 
p-value from a series of univariate analyses of correlated traits, the same analysis could be used 
to select the minimum p-value from a series of Genomic SEM models. 
 In contrast to approaches that assume homogeneity of effects across SNPs, such as 
MTAG (Turley et al., 2018), Genomic SEM includes diagnostic indices for its key assumptions, 
including a test for heterogeneity, QSNP, that can be applied at the level of the individual SNPs. 
This offers the unique ability to identify SNPs that confer specific risk to individual phenotypes, 
symptoms, or indicators. This question may be of particular interest as the large degrees of 
genetic overlap identified across phenotypes (e.g., bipolar disorder and schizophrenia) beg the 
question: what are the genetic causes of phenotypic divergence? Whereas previous GWASs have 
combined items tapping genetically-related phenotypes into a single score, or even combined 
cases with different diagnoses to obtain a shared genetic effect, Genomic SEM allows 
researchers to interrogate shared genetic effects between diagnoses or indicators, while 
concurrently testing for causes of divergence (i.e., loci that are related only to a specific 
phenotype, or subset of phenotypes, but not the more general liability). Because Genomic SEM 
relies only on GWAS summary data, it can be applied to a broad spectrum of traits, including 






Chapter 2: Validating Stratified Genomic SEM2 
INTRODUCTION 
In light of high levels of polygenicity for psychiatric traits (Hyman, 2018), it is unclear 
what stratum of genomic measurement is most useful. At the level of individual genetic variants, 
there are unlikely to be a handful of key loci that explain significant variation in comorbidity 
patterns. Zooming out to genome-wide estimates of genetic correlations is valuable with respect 
to providing an overarching sense of overlap, but this wide lens provides limited biological 
insight. Univariate methods for biological annotation, such as Stratified LD-score Regression (S-
LDSC; Finucane et al., 2015) offer a useful middle ground between individual loci and genome-
wide estimates by identifying genetic enrichment within functional annotations (e.g., genes 
expressed in the hippocampus; evolutionarily conserved genes). However, these approaches are 
currently restricted to the univariate case, and it would be inappropriate to infer enrichment of 
genetic covariance based solely on convergent univariate findings. For example, two traits may 
be highly enriched within a specific annotation, but the genetic covariance in this annotation may 
still be near 0 if the two traits are affected by a small number of disparate loci with large effects.  
Stratified Genomic SEM is an extension of the existing Genomic SEM framework 
outlined in Chapter 1. Broadly speaking, Stratified Genomic SEM fits structural models to 
genetic covariance matrices estimated within (potentially overlapping) biological categories. 
 
2 Results reported in the second chapter appear in the published work (Grotzinger et al., 2019). 
My contributions to this work included QC and gathering of the datasets, analyses, and write-up 
of the results. Grotzinger, A. D., Rhemtulla, M., de Vlaming, R., Ritchie, S. J., Mallard, T. T., Hill, W. D., ... & 
Tucker-Drob, E. M. (2019). Genomic structural equation modelling provides insights into the multivariate genetic 





These categories are constructed based on collateral gene expression data, such as that obtained 
from single-cell RNA sequencing, and from other bioinformatic annotations, such as allele 
frequency, and evolutionary conservation. Our multivariate extension of S-LDSC can be used to 
produce two types of genetic covariance matrices, S0 and S. S0 is an estimate of genetic 
covariance within a specific biological category irrespective of overlap with other categories. 
Conversely, S provides an estimate of genetic covariance controlling for overlap. The difference 
between S0 and S is similar to that between univariate and multiple regression coefficients, 
respectively.  
 The S0 and S matrices can both be used as input to the same Two-Stage Structural 
Equation Modeling framework from traditional Genomic SEM. In Stratified Genomic SEM, 
Stage 1 consists of the estimation of the stratified genetic covariance matrix and corresponding 
stratified sampling covariance matrix. This sampling covariance matrix consists of squared SEs 
on the diagonal and sampling covariances on the off-diagonal, which capture dependencies 
between sampling errors that will arise due to situations such as sample overlap. These off-
diagonals are estimated directly from our multivariate extension of S-LDSC, and thereby allow 
Stratified Genomic SEM to produce unbiased estimates for GWAS summary statistics with 
varying and unknown degrees of sample overlap. In Stage 2, an SEM is specified and parameters 
are estimated that reduce the discrepancy between the observed genetic covariance matrix (either 
S0 or S) and the model implied covariance matrix.  
METHOD 




 The point estimates and standard errors (SEs) produced by Stratified Genomic SEM were 
evaluated using simulation. As partitions may overlap substantially, an additional goal was to 
determine whether Stratified Genomic SEM can produce unbiased estimates that are specific to 
the causal partition of interest. The expectation is that the zero-order genetic covariance matrices 
(S0) will not show partition specificity due to the noted partition overlap. Conversely, the 
expectation is that the  covariance matrices (S)—which reflect the covariances estimated 
within a multiple regression framework—would demonstrate the desired specificity in estimates. 
The first step in the simulation procedure was to generate 100 sets of 45, 100% heritable 
phenotypes (“orthogonal genotypes”) using the GCTA package (Yang et al., 2011). Each 100% 
heritable phenotype was specified to have 10,000 randomly selected causal variants from within 
a particular partition. These phenotypes were paired with genotypic data for 100,000 randomly 
selected, unrelated individuals of European descent from UKB data for the 1,209,498 SNPs 
present in HapMap3.  
The simulated genotypes were used to construct six different factor structures for six 
causal partitions. All orthogonal genotypes were scaled M=0, SD=1. For three of the causal 
partitions (DHS Peaks, H3K27ac, and PromoterUSC) seven genotypes for each partition were 
used to construct six new correlated genotypes, each as the weighted linear combination of a 
domain-specific genetic factor and a general genetic factor, which was constructed from the 
seventh genotype. For the remaining three causal partitions (FetalDHS, H3K9ac, and TFBS) 
eight genotypes for each partition were used to construct two sets of three correlated genotypes 
for two correlated general genetic factors, constructed from the seventh and eighth genotypes. A 




six causal partitions. As each genotype within each partition was specified to have 10,000 causal 
SNPs, the “total’ genotypes created as the sum of six partition had 60,000 causal SNPs in the 
population generating model. 
Phenotypes were subsequently constructed as the weighted linear combination of one of 
the six “total” genotypes and domain-specific environmental factors (randomly sampled from a 
normal distribution with M=0, SD=1). Heritabilities for phenotypes 1-6 were all set to ℎ𝑘
2=60%, 
such that the weights for the genotypes were √ℎ𝑘
2 and the weights for the environmental factors 
were √(1 − ℎ𝑘
2). Each of the 600 phenotypes (100 sets of 6 phenotypes) was then analyzed as a 
univariate GWAS in PLINK (Purcell et al., 2007) to produce univariate GWAS summary 
statistics. The summary statistics were munged using the base GenomicSEM R package, and 
Stratified Genomic SEM coupled the 1000 Genomes Phase 3 BaselineLD Version 2.2 
annotations was used to construct 100 sets of  6×6 stratified, zero-order genetic covariance 
matrices (0),  covariance matrices (S), and their corresponding sampling covariance matrices 
(VS0 and VS ).   
RESULTS 
Validating Stratified Zero-Order Genetic Covariances: S0 and VS0 
For the genetic covariance (S0) matrix, the expectation is that the partition including all SNPs—
the baseline (i.e., genome-wide) partition—will reflect the additive combination of the 
population generating covariance matrices specified for the six causal partitions. For the six 
causal partitions, the expectation is that the estimated covariance matrix will reflect a 
combination of the generating model in that partition plus the generating model in the other 




these expectations, average observed covariance matrices were created across the 100 
simulations for the genome-wide annotation and six causal annotations. The estimated genome-
wide model approximately reflected an additive mixture of the six population generating 
covariance matrices, and was estimated with minimal bias (absolute value of mean discrepancy = 
.004; Figure 4). In addition, the observed covariance matrices within the causal partitions were, 
generally speaking, minimally biased relative to expectation (Figure 4; Table 1).   
In order to evaluate SE performance, the ratio of the mean SE estimate was analyzed 
across the 100 simulations over the empirical SE (calculated as the standard deviation of the 
parameter estimates across the 100 simulations). A value above 1 for this ratio, therefore, 
indicates conservative SE estimates. This ratio was calculated within each of the partitions and 
for each cell of the covariance matrix. The average ratio across partitions and cells of the 
covariance matrix was 1.030 (Figure 5 for distribution across all partitions; Table 1 for ratio 
within causal partitions). Thus, the multivariate extension of S-LDSC produces a SE estimate for 
stratified heritability and covariance that performs as expected. In fact, these estimates are very 
slightly conservative as the mean SE was slightly larger than the empirical SE. Moreover, the 
average Z-statistic for heritability and covariance estimates within the causal partitions were all 
highly significant, suggesting more than adequate power when using the parameters of the 







Table 1. Zero-order (S0) and S Covariance Results  
    Zero-Order Results     
Partition % HM3 SNPs SE Ratio 
Absolute Mean 
Difference 
Average h2             
Z-Statistic 
Average 
Covariance        
|Z-statistic| 
Baseline 100% 0.956 0.004 36.99 24.85 
DHS Peaks 16.80% 0.992 0.031 10.76 7.68 
FetalDHS 12.95% 1.041 0.069 11.12 7.73 
H3K27ac 45.10% 1.034 0.141 31.79 21.17 
H3K9ac 16.20% 1.102 0.02 14.52 9.42 
Promoter 5.65% 1.017 0.09 11.12 7.06 










Average  h2          
Z-statistic 
Average 
Covariance        
|Z-statistic| 
Baseline 100% 1.016 0.564 -2.64 -1.86 
DHS Peaks 17% 0.988 0.008 1.74 1.51 
FetalDHS 0% 1.034 0.006 2.85 1.98 
H3K27ac 1% 1.034 0.013 2.62 1.85 
H3K9ac 1% 1.043 0.006 2.81 1.57 
Promoter 0% 1.034 0.007 5.72 3.52 
TFBS 0% 1.034 0.003 2.99 1.72 


























































































































































































































































































































































Figure 4a. Population Generating and Observed Zero-order (S0) Covariance Matrices. The 
first column depicts the genetic covariance matrix in the generating population. The second 
column depicts the average observed covariance across the 100 simulations runs. The last 
column reflects the difference between the population matrix and average observed covariance 
matrix. For the zero-order matrices, estimates are expected to be biased in the sense that an 
individual partition will be affected by population generating covariances in overlapping 
partitions. Results are shown for the DHS Peaks (top row), Fetal DHS (middle row) and 































































































































































































































































































































































































































































Figure 4b. Population Generating and Observed Zero-order (S0) Covariance Matrices. The first 
column depicts the genetic covariance matrix in the generating population. The second column depicts the 
average observed covariance across the 100 simulations runs. The last column reflects the difference 
between the population matrix and average observed covariance matrix. For the zero-order matrices, 
estimates are expected to be biased in the sense that an individual partition will be affected by population 
generating covariances in overlapping partitions. Results are shown for the H3K9ac Peaks (top row), 
PromoterUSC (second row), TFBS (third row), and genome-wide (bottom row) partitions. Results for 



















Figure 5. Distributions of SE Ratios. Panels depict mean SE ratios across the 100 simulations 
for the for mean SE over the empirical SE across the partitions for the S (right panel) and zero-
order (left panel) covariance matrices. Average ratios are shown for each cell of the covariance 
matrix for all partitions.  
 
Validating Stratified  Covariance : S and VS 
The expectation for the genetic S covariance matrices is that the observed covariance 
matrices will reflect the generating model within only that partition. Indeed, the causal partitions 
closely matched their respective population generating covariance matrices and bias was 
minimal (Table 1; Figure 6). The ratio of the mean SE estimate across the 100 runs over the 
empirical SE (calculated as the standard deviation of the parameter estimates across the 100 runs) 
was subsequently evaluated. The average ratio of SE estimates was 1.014 across all partitions 
(Figure 5) and, importantly, was also close to 1 for the causal partitions (Table 1). Results for 
4,459 of the total 5,300 covariance matrices produced negative heritability estimates. This 
included some of the causal partitions (Table 1), but was largely true for the non-causal 
partitions. Negative heritability estimates are unsurprising for the non-causal partitions as their 




around 0 that includes negative values due to sampling variation. The Z-statistics for the  
heritabilities and covariances were, on average, smaller relative to the zero-order covariance 
matrices (Table 1). This is to be expected as the zero-order (S0) covariance matrices include 
power gained from variance shared with overlapping partitions.  
 The S covariance matrices for the causal partitions were then used as input for Genomic 
SEM models. The two types of population generating models—a common factor and correlated 
factors model—were run for each partition. For all causal partitions, Genomic SEM estimates 
closely matched the parameters specified in the generating population (Figure 7). In addition, the 
ratio of the mean model SEs over the empirical SEs was near 1. Model fit statistics (CFI, AIC, 
and model 2) also generally favored the generating model for a particular partition (Table 2). 
This was least true for the H3K27ac partition. This is unsurprising as the population generating 
model for the H3K27ac partition—a correlated factors model with a factor correlation of .7—
most closely matched the competing common factor model. Collectively, these results indicate 
that stratified Genomic SEM produces unbiased parameter estimates and standard errors for S0 
and S, that S shows specificity to the causal partitions of interest, and that model fit indices 



































































































































































































































































































































































Figure 6a. Stratified S Covariance Matrices. The first column depicts the genetic covariance 
matrix in the generating population. The second column depicts the average observed covariance 
across the 100 simulations runs. The last column reflects the difference between the population 
matrix and average observed covariance matrix. As observed, for the S  matrices, estimates are 
expected to be generally unbiased. Results are shown for the DHS Peaks (top row), Fetal DHS 



























































































































































































































































































































































Figure 6b. Stratified S Covariance Matrices. The first column depicts the genetic covariance 
matrix in the generating population. The second column depicts the average observed covariance 
across the 100 simulations runs. The last column reflects the difference between the population 
matrix and average observed covariance matrix. As observed, for the S  matrices, estimates are 
expected to be generally unbiased. Results are shown for the H3K9ac Peaks (top row), 
PromoterUSC (second row), TFBS (third row), and genome-wide (bottom row) partitions. 
Results for genome-wide estimates are unaffected by overlap with other partitions as the 








































Figure 7a. Genomic SEM Simulation Results for DHS Partition. Parameters outside of the 
parentheses indicate those provided in the generating population. In parentheses, we provide n 
the average point estimate and the ratio of the mean SE estimate across the 100 runs over the  
empirical SE (calculated as the standard deviation of the parameter estimates across the 100 
runs). We note that SE estimates are expected to be upwardly biased in the standardized case, 
and for residual variances, due to upper or lower limits on the sampling distributions (e.g., 







































Figure 7b. Genomic SEM Simulation Results for FetalDHS Partition. Parameters outside of 
the parentheses indicate those provided in the generating population. In parentheses, we provide 
n the average point estimate and the ratio of the mean SE estimate across the 100 runs over the 
empirical SE (calculated as the standard deviation of the parameter estimates across the 100 
runs). We note that SE estimates are expected to be upwardly biased in the standardized case, 
and for residual variances, due to upper or lower limits on the sampling distributions (e.g., 








































Figure 7c. Genomic SEM Simulation Results for H3K27ac Partition. Parameters outside of 
the parentheses indicate those provided in the generating population. In parentheses, we provide 
n the average point estimate and the ratio of the mean SE estimate across the 100 runs over the 
empirical SE (calculated as the standard deviation of the parameter estimates across the 100 
runs). We note that SE estimates are expected to be upwardly biased in the standardized case, 
and for residual variances, due to upper or lower limits on the sampling distributions (e.g., 







































Figure 7d. Genomic SEM Simulation Results for H3K9ac Partition. Parameters outside of 
the parentheses indicate those provided in the generating population. In parentheses, we provide 
n the average point estimate and the ratio of the mean SE estimate across the 100 runs over the 
empirical SE (calculated as the standard deviation of the parameter estimates across the 100 
runs). We note that SE estimates are expected to be upwardly biased in the standardized case, 
and for residual variances, due to upper or lower limits on the sampling distributions (e.g.,  









































Figure 7e. Genomic SEM Simulation Results for PromoterUSC Partition. Parameters 
outside of the parentheses indicate those provided in the generating population. In parentheses, 
we provide n the average point estimate and the ratio of the mean SE estimate across the 100 
runs over the empirical SE (calculated as the standard deviation of the parameter estimates across 
the 100 runs). We note that SE estimates are expected to be upwardly biased in the standardized 
case, and for residual variances, due to upper or lower limits on the sampling distributions (e.g., 








































Figure 7f. Genomic SEM Simulation Results for TFBS Partition. Parameters outside of the 
parentheses indicate those provided in the generating population. In parentheses, we provide n 
the average point estimate and the ratio of the mean SE estimate across the 100 runs over the 
empirical SE (calculated as the standard deviation of the parameter estimates across the 100 
runs). We note that SE estimates are expected to be upwardly biased in the standardized case, 
and for residual variances, due to upper or lower limits on the sampling distributions (e.g., 










DHS Peaks 81% 89% 87% 
FetalDHS 96% 82% 92% 
H3K27ac 63% 72% 72% 
H3K9ac 56% 56% 56% 
Promoter 85% 91% 85% 
TFBS 93% 89% 90% 
Note. Results reflect the proportion of runs favoring the 
population generating model relative to a close alternative 
model (either a common factor or correlated factors 
model). For example, a common factor model was 
specified in the generating population for DHS peaks, and 
then a common and correlated factors model were 
compared with respect to model indices for each of the 100 
runs of the simulation.  
 
DISCUSSION 
 In order to utilize a Genomic SEM framework to model partitioned genetic covariance 
across psychiatric traits, we first validated a multivariate extension of S-LDSC. The estimation 
of partition-specific genetic covariance represents a substantive addition to the existing S-LDSC 
method, particularly with respect to understanding genetic overlap across traits. For example, it 
may be that the heritability of both schizophrenia and bipolar disorder is highly enriched in fetal 
brain cells, but that this enrichment is uninformative with respect to genetic overlap. That is, the 
genetic covariance within this partition may still be near 0, despite enrichment for each disorder 
within the partition, if the disorders are affected by a small number of disparate loci with large 




be characterized by high genetic covariance if both disorders are affected by large sets of 
overlapping loci with relatively small effects.  
After validating the multivariate extension of S-LDSC, we verified that stratified genetic 
covariance matrices could be as input into the general Genomic SEM framework. These results 
revealed that Genomic SEM produced model parameter estimates that matched the generating 
population, that SEs are estimated with minimal bias, and that model fit statistics appropriately 
favor the generating model within a particular partition. Pairing stratified genetic covariance 
matrices with a Genomic SEM framework opens up the door for a number of analytic 
possibilities. This includes the ability to formally model genetic enrichment a the level of 
overarching genetic factors. In the next Chapter, this particular application is used to identify 














Chapter 3: Application of Genomic SEM to Interrogate Genetic Overlap Across 11 
Psychiatric Traits3 
INTRODUCTION 
 Comorbidity is the rule rather than the exception for mental health disorders (Kessler et 
al., 2005). In addition to comorbidity among diagnostic categories, continuous dimensions of 
liability to psychopathology overlap across domains, with elevated symptoms in one continuous 
domain associated with elevated symptoms in other domains (Smoller et al., 2018). Recent 
findings indicate that this comorbidity is captured by a latent, general psychopathology factor 
that is commonly known as the p-factor and is widely supported based on previous results (Caspi 
& Moffitt, 2018; Caspi et al., 2013; Pettersson, Larsson, & Lichtenstein, 2016; Smoller et al., 
2018; Stochl et al., 2015). Observed patterns of comorbidity might arise, in part, due to genetic 
variants with downstream effects on multiple mental health disorders.  
The argument could be made that phenotypic comorbidity is merely a reflection of 
disorders causing other disorders, or key symptoms causing multiple symptom clusters (i.e., 
bridge symptoms in a network model), as opposed to shared biological causes. However, 
bivariate genomic methods such as genomic-relatedness-based restricted maximum-likelihood 
(GREML; Yang et al., 2011) and LDSC (Bulik-Sullivan et al., 2015) allow for the estimation of 
genetic correlation of mental health outcomes in largely non-overlapping participant samples. As 
 
3 Results reported in the third chapter appear in the preprint from (Grotzinger et al., 2020). My 
contributions to this work included QC and gathering of the datasets, simulations, analyses, and 
write-up of the results. Grotzinger, A. D., Mallard, T. T., Akingbuwa, W. A., Ip, H. F., Adams, M. J., Lewis, C. 
M., ... Tucker-Drob, E.M., & Nivard, M.G. (2020). Genetic Architecture of 11 Major Psychiatric Disorders at 






these methods indicate high levels of genetic overlap across mental health traits, this provides 
compelling evidence for common genetic correlates of psychiatric risk. However, existing 
molecular genetic methods do not permit the data generating processes of the observed, genetic 
correlations to be investigated systematically. Having developed and validate both Genomic 
SEM, and its extension Stratified Genomic SEM, the present chapter sought to apply these 
multivariate genomic methods to gain greater insight into genetic risk sharing across a wide array 
of psychiatric traits.  
METHOD 
Psychiatric Genomic Data 
GWAS summary statistics were utilized for eleven major psychiatric disorders: attention-
deficit/hyperactivity disorder (ADHD; Demontis et al., 2019), alcohol use disorder (AUD; 
Walters et al., 2018), anorexia nervosa (AN; Watson et al., 2019), autism spectrum disorder 
(ASD; Grove et al., 2019), anxiety disorders (ANX; Otowa et al., 2016; Purves et al., 2019), 
bipolar disorder (BIP; Stahl et al., 2019), major depressive disorder (MDD; Howard et al., 2018; 
Wray et al., 2018), obsessive compulsive disorder (OCD; International Obsessive Compulsive 
Disorder Foundation et al., 2018), post-traumatic stress disorder (PTSD; Duncan et al., 2017; 
Meier et al., 2018), schizophrenia (SCZ; [forthcoming]), and Tourette’s syndrome (TS; Yu et al., 
2019). Summary statistics were obtained from a range of sources, including the Psychiatric 







Table 3. Contributing Cohorts for 11 Psychiatric Traits   
Trait Data Source Cases Controls 
ADHD 
23andMe 5,017 57,363 
PGC 19,099 34,194 
Total 24,116 91,557 
SCZ PGC 53,386 77,258 
ANX 
ANGST 5,540 11,770 
UKB 25,453 58,113 
Total 30,993 69,883 
ASD PGC 18,382 27,969 
BIP PGC 20,352 31,358 
MDD 
PGC + 23andMe 135,458 344,901 
UKB 113,769 208,811 
Total 249,227 553,712 
PTSD 
iPSYCH 9,831 19,225 
PGC 23,212 151,447 
Total 33,043 170,672 
TS PGC 4,819 9,488 
ALCH 
PGC 8,485 20,272 
UKB 147,267 
Total  155,697 
OCD PGC 2,688 7,037 
AN PGC 16,992 55,525 
Note. Sample sizes reported are for the European only subsets of the summary statistics. 
The broad depression phenotype was specifically used from the UKB Major Depression 
GWAS. The lifetime anxiety disorder phenotype was used for the UKB Anxiety GWAS. 
We note that the total sample sizes listed are the raw totals and do not reflect effective 
sample sizes. 
 
The original articles contain details for the corresponding univariate GWAS about sample 
ascertainment, quality control, and related procedures. For five phenotypes—MDD, ADHD, 
ANX, PTSD, and ALCH— GWAS summary statistics were meta-analyzed across two different 
contributing cohorts. Meta-analyses of the same phenotype for PTSD, MDD, ADHD, ANX, and 
ALCH were conducted in Genomic SEM by specifying a model in which each SNP predicted a 
latent genetic factor defined by the two phenotypes with fixed loadings of 1. This model is 




Selection and Creation of Functional Annotations 
 In order to construct the genome-wide S-LDSC matrix, and estimate stratified genetic 
covariance, pre-computed annotation files provided by the original S-LDSC authors were used 
(Finucane et al., 2015). In line with recommendations, all annotations were included from the 
most recent 1000 Genomes Phase 3 BaselineLD Version 2.2 (Hujoel, Gazal, Hormozdiari, van 
de Geijn, & Price, 2019) that includes a total of 97 annotations ranging from coding, UTR, 
promoter, and flanking window annotations. For tissue specific histone marks, we included 
annotations constructed based on data from the Roadmap Epigenetics Project (Kundaje et al., 
2015) for narrowly defined peaks for DNase hypersensitivity, H3K27ac, H3K4me1, H3K4me3, 
H3K9ac, and H3K36me3 chromatin. For tissue specific gene expression, annotations were 
included that were previously constructed based on RNA sequencing data from human tissues 
from GTEx (Consortium, 2015) and for annotations constructed from human, mouse, and rat 
microarray experiments from the Franke Lab (i.e., DEPICT; Pers et al., 2015). For both tissue 
specific histone/chromatin marks and gene expression, we utilized only brain and endocrine 
relevant regions in addition to 5 randomly selected control regions (e.g., epidermal tissue 
expression) from each (i.e., 10 controls total).  
Twenty-nine annotations were additionally created to examine the interaction between 
protein-truncating variant (PTV)-intolerant (PI) genes and human brain cells. Protein-truncating 
variant (PTV)-intolerant (PI) genes were obtained from the Genome Aggregation Database 
(gnomAD), and ascertained using the probability of loss-of-function intolerance (pLI) metric. 
We selected genes with pLI > 0.9, producing a list of 3063 genes (Karczewski et al., 2019). 




on the Genotype-Tissue Expression (GTEx) project brain tissues (Habib et al., 2017). We 
selected sporadic genes and genes with low expression for the 14 cell types in the top 1600 
(~15%) differentially expressed genes in each cell type, which likely cover all genes that are 
important for a specific cell type. PI x human brain cell gene sets contained the intersection of 
genes that are PTV-intolerant and each human brain cell gene set. Annotations were created 
using a 100kb window and LD information from the European subsample of 1000 Genomes 
Phase 3.  
All continuous annotations and flanking window annotations were excluded for 
enrichment of psychiatric factors for a total of 168 binary annotations across the baseline model, 
gene expression, histone marks, and PI and neuronal gene annotations. For a Bonferroni 
correction < .05 this corresponds to p < 2.98E-4. The continuous annotations were retained for 
construction of the genome-wide, S-LDSC matrix.   
Estimating Genetic Enrichment of Model Parameters 
 Genetic enrichment within a functional annotation reflects the extent to which the per-
SNP heritability within that category is greater relative to the per-SNP heritability outside of that 
category. Put another way, genetic enrichment indexes whether the ratio of the proportion of 
heritability accounted for by a certain class of SNPs over the proportion of SNPs within that 















where 𝜃|𝐶| reflects the estimate for a model parameter within a functional category, 𝜃 reflects 
the genome-wide parameter estimate, 𝑀|𝐶| is the number of SNPs within the same functional 
category, and M is the total number of SNPs used to estimate genome-wide heritability. In order 
to obtain a SE for this ratio, enrichment is estimated for factor variances in the context of 
Stratified Genomic SEM using a two-step procedure. In Step 1, a model is estimated using the 
genome-wide S-LDSC matrix in which unit variance identification is used (i.e., factor variances 
fixed to 1). In Step 2, the freely estimated parameters from the previous model are fixed and the 
previously fixed parameter, and its SE, are freely estimated across the stratified genetic 
covariance matrices. This estimate in Step 2 reflects the proportion of the parameter of interest 
(e.g., psychiatric factor variance) accounted for by the genetic covariance structure within a 
given functional category (i.e., the numerator of the equation). This proportional estimate, and its 
SE, are subsequently divided by the proportion of SNPs in that category (i.e., the denominator of 
the equation). For clarification, we note that genome-wide enrichment across all SNPs is exactly 
equal to 1. That is, for Step 2, if the genome-wide matrix is used as input this reproduces a 
parameter estimate of 1, that is then divided by a proportion of 1, which reflects the ratio of M/M 
(i.e., all SNPs over all SNPs).  
Quality Control Procedures  
LD-Score Regression. Quality control (QC) procedures for producing the S and VS matrix 
followed the defaults in LDSC. This included removing SNPs with an MAF < 1%, information 
scores (i.e., imputation quality scores) < .9, SNPs from the MHC region due to unique LD 




imputed in the absence of imputation information. The LD scores used for the analyses presented 
were estimated from 1000 Genomes Phase 3, but restricted to HapMap3 SNPs.  
Multivariate GWAS. Summary statistics are only restricted to HapMap3 SNPs for the 
estimation of the genetic covariance and sampling covariance matrix in LDSC, whereas all SNPs 
passing QC filters are included for multivariate GWAS. To obtain summary statistics for 
multivariate GWAS, we recommend using QC procedures of removing SNPs with an MAF < .01 
in the reference panel, and those SNPs with an INFO score < 0.6. MAFs were obtained for the 
current analyses using the 1000 Genomes Phase 3 reference panel. Using these QC steps, 
4,775,763 SNPs were present across all 11 psychiatric traits. The regression effects for the 
univariate indicators were standardized using the procedure for logistic coefficients outlined 
above.  
Identification of Top Hits (Clumping) and Overlapping Hits 
 Lead SNPs for meta-analyzed univariate indicators and the latent genetic factors were 
identified using the clumping and pruning algorithm in FUMA (Watanabe, Taskesen, Van 
Bochoven, & Posthuma, 2017). Independent significant SNPs were defined as crossing the 
genome-wide significance threshold of p < 5e-8 that were independent from other SNPs at r2 < 
0.1. We used pre-calculated LD from European 1000 Genomes Phase 3 reference panel to 
identify independent SNPs. Top loci were subsequently identified by merging any SNPs in close 
proximity (< 250 kb) into a single genomic locus such that an individual locus could include 
multiple independent SNPs at r2 < 0.1. This same pipeline was used for the full set of univariate 
summary statistics (i.e., not listwise deleted) in order to determine whether the factor hits were 




throughout the paper) in the manhattan plots. To identify overlap with other traits we identified 
all independent SNPs that were in LD (r2 < 0.1) with independent SNPs for the individual traits. 
As LD structure can vary across different cohorts, we also considered SNPs to be overlapping/in 
LD with hits from the univariate studies if they were within a 250 kb window (125 kb on either 
side of the index variant) for loci identified for the psychiatric factors, hierarchical factor, and 
omnibus test described in the multivariate GWAS section below.  
RESULTS 
Factor Analysis of Genetic Covariance across 11 Psychiatric Traits 
A heatmap of the genetic correlations across the 11 psychiatric traits clearly indicates 
both pervasive overlap across traits and tighter clustering among certain subgroups of traits 
(Figure 8a). Using a combination of exploratory and confirmatory models, we sought to identify 
the genome-wide, multivariate architecture that most closely approximated the observed patterns 
of genetic overlap. In order to explore the full-scope of factors solutions, EFAs were conducted 
using the factanal R package for two to five factor solutions using both oblique rotations, which 
allow for correlations among the latent factors, and orthogonal rotations, which assumes factors 
are independent (i.e., uncorrelated). Orthogonal rotations were examined in order to identify 
maximally separable dimensions with distinct sets of psychiatric indicators. The exploratory 
factor analyses (EFAs) were conducted for the genetic correlation structure derived from odd 
chromosomes only, excluding chromosome 23.  
Confirmatory factor analyses (CFAs) specified on the basis of these EFAs were fit to a 
genetic correlation matrix estimated using only even chromosomes. Using odd and even 




provided a form of cross-validation to guard against model overfitting. Confirmatory models 
based on orthogonal EFA results allowed for freely correlated factors, as pruning factor loadings 
will often reintroduce factor correlations. A single common factor model was also considered. 
All CFAs were fit using the Weighted Least Squares (WLS) estimator in the GenomicSEM R 
package. 
For the CFAs, factors were assigned to traits when their standardized loading exceeded 
.35 in the corresponding EFAs, with two exceptions. First, for all EFAs with > 3 factors, a factor 
was identified with Tourette’s Syndrome (TS) as its only indicator with standardized loading 
>.35. Assigning TS to all factors at once, or to one factor at a time, resulted in issues with model 
convergence. Consequently, this final factor was removed in the CFA and TS was specified to 
always load on the factor with the largest EFA loading (excluding the factor defined only by TS) 
and models were compared where TS loaded onto one of the remaining factors. Among these 
combinations of TS models, a final model was selected using model fit indices (i.e., AIC, 
SRMR, and CFI). Second, for certain EFA solutions, there were traits that did not meet the 
standardized loading criteria of .35 for any factor. For these traits, factors were assigned when 
their standardized loading exceeded a more lenient threshold of 0.2. Model fit indices were then 
inspected for the follow-up CFA model to confirm that including those factor loadings provided 
better fit to the data.  
CFAs specified based on the 5-factor correlated and uncorrelated rotations were similar 
in both factor structure and fit to the data. In addition, both 5-factor models provided far superior 
fit to the data, relative to the other models, with a number of the other CFAs failing to converge 




this ultimately provided the best fit to the data. Importantly, the model identified using a split of 
even and odd chromosomes also fit the data well when applied to the genome-wide matrix 
estimated using chromosomes 1-22 (Figure 8b; 2[33] = 161.66, AIC = 227.66, CFI = .975, 
SRMR = .072).  
Table 4. Confirmatory Model Comparisons  
CFA based on: df AIC CFI  SRMR 
Common Factor 44 645.48 0.730 0.136 
Oblique Rotation  
2 Factor EFA No Convergence 
3 Factor EFA No Convergence 
4 Factor EFA 39 575.23 0.767 0.109 
5 Factor EFA 37 226.35 0.936 0.084 
Orthogonal Rotation 
2 Factor EFA No Convergence  
3 Factor EFA No Convergence 
4 Factor EFA 36 309.54 0.897 0.120 
5 Factor EFA 33 192.85 0.955 0.078 
Hierarchical  35 235.44 0.933 0.091 
Note. CFAs, for which model fit estimates are presented here, were 
estimated using LDSC-estimated genetic correlations for even numbered 
chromosomes only. They were fit based on results from EFAs for 
estimated using genetic correlations for odd chromosomes, excluding 
chromosome 23. The hierarchical model was fit to the solution based on 
the 5 factor orthogonal EFA. 
 
For this model, Factor 1 largely consists of disorders characterized by compulsive 
behaviors (AN, OCD, TS), Factor 2 is characterized by psychotic disorders (SCZ, BIP), Factor 3 
is defined primarily by childhood onset neurodevelopmental disorders (ADHD, AUT), and 
Factor 4 is a fundamentally internalizing factor (ANX, MDD). The fact that AUD loads on the 
last three factors is consistent with the psychosocially, multidetermined nature of alcohol risk. 




remainder of the text. These results largely replicate PGC Cross-Disorder Group 2 (PGC-CDG2; 
Lee et al., 2019) analyses based on a subset of variables, and earlier GWAS releases, of those 
used here. More specifically, PGC-CDG2 reported factors representing compulsive, psychotic, 
and neurodevelopmental disorders, which correspond closely to our first three factors. The 
moderate factor correlations were also suggestive of a hierarchical factor structure. Indeed, a 
hierarchical model also fit the data well (Figure 1c; 2[35] = 171.37, AIC = 233.37, CFI = .974, 
SRMR = .079), tentatively suggesting the presence of a higher-order, general psychopathology 











































Figure 8. Heatmap of Genetic Correlations and Factor Models. Panel A: Genetic correlations estimated using LDSC. Panel B: 
Figure presents standardized results for the correlated factors model fit to the genome-wide LDSC genetic covariance matrix. Panel 
C: Figure presents standardized results for hierarchical factor model fit to genome-wide LDSC genetic covariance matrix. Standard 
errors are not shown for the hierarchical model as this is not currently available for models with factors as outcomes. For both Panels 
B and C, indicators are presented as circle to reflect the fact that these are unobserved heritability estimates. ADHD = attention-
deficit/hyperactivity disorder; OCD = obsessive-compulsive disorder; TS = Tourette’s syndrome; PTSD = post-traumatic stress 
disorder; AN = anorexia nervosa; AUT = autism spectrum disorder; ALCH = alcohol use disorder; ANX = anxiety; MDD = major 




Genetic Enrichment of Psychiatric Factors (Stratified Genomic SEM) 
 Enrichment results for the compulsive disorders factor are not considered as these 
findings were nonsignificant due to the relatively reduced power of the contributing psychiatric 
indicators (AN, OCD, TS). Overall, 40 annotations were significant using a Bonferroni 
correction < 5% for 168 annotations for psychotic disorders, 1 annotation (the conserved primate 
annotation) for neurodevelopmental disorders, 4 annotations for internalizing disorders, and 38 
annotations for the p-factor. In line with prior findings for complex traits more generally 
(Finucane et al., 2015), conserved functional annotations were highly enriched across the 
psychiatric factors. However, the conserved primate region was particularly enriched for the 
neurodevelopmental, internalizing, and p-factor, and the Genomic Evolutionary Rate Profiling 
(GERP) annotation (another conserved annotation) for the neurodevelopmental and internalizing 
factors (Figure 9A). Also in line with findings for complex traits (Gazal et al., 2017), genetic 
enrichment increased slightly across the allele frequency spectrum for the minor allele frequency 
(MAF) bin annotations (Figure 9B). This may seem initially counterintuitive under a model of 
negative selection, but it is important to remember that less common variants with the same per-
allele effect size as more common variants will explain less heritability (variance) in the 
population due to their low frequency (Gazal et al., 2017). While larger enrichment for lower 
frequency variants is possible under very strong negative selection, the present findings line up 











































Figure 9. Genetic Enrichment of Factors. Figure depicts enrichment of psychotic (shown in red), 
neurodevelopmental (shown in gold), and internalizing factors (shown in purple) from the correlated 
factors model and the second-order p-factor (shown in light blue) for the baseline annotations (panel A), 
gene expression annotations (panel B), minor allele frequency annotations (MAF; panel C), histone 
mark annotations (panel D), neuronal gene annotations (panel E), and neuronal × PI gene annotations 
(panel F). Results for the compulsive disorders factor are not depicted due to the relatively low power of 
these results. For panels A, B, and D, only the top ten annotations across the factors are depicted within 
each of the functional categories. The black dashed line reflects the null (enrichment = 1). Error bars 




The most significant histone marker effect for psychotic disorders was for the inferior 
temporal lobe H3K27ac, a region previously shown to be enriched for common epilepsies (Marzi 
et al., 2018). The most enriched annotation for the neurodevelopmental disorders factor was fetal 
female brain DNase, a region that was also enriched across the psychotic and internalizing 
disorders. For internalizing disorders, the most significant annotation was fetal male brain 
H3K4me1, a region also enriched for psychotic disorders and the p-factor. Both fetal female 
brain DNAse and fetal male brain H3K4me1 have been previously reported to be enriched for 
general liability across psychiatric disorders (Schork et al., 2019). As the opposite-sex 
counterpart for each of these annotations (e.g., fetal male brain DNAse) were also generally 
enriched, though to a slightly lesser degree, it is currently unclear whether this enrichment 
pattern offers insight into sex-specific base rates for different disorders. In line with previous 
results for earlier releases of schizophrenia summary statistics (Finucane et al., 2015), fetal 
female brain H3K4me3 region was enriched for psychotic, internalizing disorders, and the p-
factor. The most significant histone annotation for the p-factor was dlPFC H3K27ac.  
For gene tissue expression, we observe that brain regions are generally enriched, as is 
also observed for other complex traits, but were most enriched for psychotic disorders (Figure 
4d; Finucane et al., 2018). As these functional categories become more refined, the enrichment 
signal may begin to delineate between more nuanced, neuroanatomical sub-regions and 
categories. To this end, 29 new annotations were created in order to examine the effects of 
neuronal genes, protein-truncating variant (PTV)-intolerant (PI) genes that are particularly likely 
to modify gene function, and their intersection. These results revealed that these functional 




significantly enriched gene sets falling in this category. Moreover, specific intersections of PI-
PTV and neuronal genes were more enriched than others, with the interaction of PI-PTV genes 
and GABA2 and exCA1 displaying the most significant enrichment for psychotic disorders. As 
PI-PTV genes have previously been found to be enriched for AUT, ADHD, BIP and SCZ 
(Ganna et al., 2018), these results shed light on specific neuronal subcategories that delineate 
between classes of disorders within PI-PTV gene sets. The final set of analyses sought to identify 
risk conferring loci for the psychiatric factors.   
QSNP Estimation 
In the context of the multivariate GWAS for the correlated factors model, four separate 
follow-up  models were estimated in which the SNP predicted three of the overarching factors 
and the indicators of the remaining fourth factor. Comparing the model 2 between the model in 
which the SNP predicted all four factors to one of these four follow-up models produces a factor-
specific QSNP. QSNP indexes violation of the null hypothesis that the SNP acts through a given 
factor. Put another way, it quantifies whether the individual SNP is more likely to operate 
through the common pathways of the psychiatric factor, or the independent pathways of 
individual disorders. For the hierarchical factor structure, we compared the model 2 for a model 
in which the SNP predicted only the second-order, p-factor, to a model in which the SNP 
predicted only the four, first-order psychiatric factors. For the hierarchical model, QSNP indexes 
heterogeneity at the level of the psychiatric factors (i.e., deviation from the null that the SNP 






Multivariate GWAS in Genomic SEM 
As the schizophrenia summary statistics are not publicly available at the time of writing 
this dissertation, specific hits are not reported, but will be presented when submitted for 
publication. For the purpose of this dissertation, general trends are reported in tables and figures. 
To begin with, a maximally complex model in which the target SNP was allowed to have direct 
regression relations with each of the 11 psychiatric phenotypes was compared against a null 
model in which the 11 regression relations were fixed to zero. This omnibus test is 2 distributed 
with 11 df, and quantifies whether there is an overall effect of the SNP across the phenotypes, 
irrespective of the directionality of the effect. For the omnibus meta-analysis, we identified 184 
hits, 39 of which were not in LD with any of the univariate hits (Table 5; Figure 10 for 
Manahattan plots; Figure 11 for QQ-plots). Of these 39 novel hits, 9 have not been described for 
outside studies of psychiatric traits/symptoms and were largely characterized by hits previously 
found for cognitive (e.g., intelligence) or anthropometric traits (e.g., BMI). Moreover, 7 hits 
were entirely novel in that they were not in LD with any previously discovered hits in the GWAS 
catalogue. For comparative purposes, we consider overlap with results from PGC-CDG2 (Lee et 
al., 2019) given both overlapping datasets and research questions. For the omnibus meta-











































Figure 10. Manhattan Plots for Psychiatric Factors. Genomic SEM was used to conduct a multivariate 
GWAS from the correlated factors model for compulsive disorders (Factor 1; panel A), psychotic disorders 
(Factor 2; panel B), neurodevelopmental disorders (Factor 3; panel C), and internalizing disorders (Factor 
4; panel D) using the genome-wide LDSC matrix. Panel E depicts results from the omnibus test across all 
11 psychiatric traits. Panel F depicts the results of the SNP effect on the second-order general liability 
factor from the hierarchical model. The top half of the plots depicts the -log10(p) values for SNP effects on 
the factor; the bottom half depicts the log(10)p values for the factor specific QSNP effects. The gray dashed 
line marks the threshold for genome-wide significance (p < 5 × 10-8). Black triangles denote independent 
factor hits that were in LD with hits for one of the univariate indicators and were not in LD factor-specific 
QSNP hits. Large red triangles denote novel loci that were not in LD with any of the univariate GWAS or 







































Figure 11. QQ-plots for Multivariate GWAS. Expected −log10(p)-values are those expected 
under the null hypothesis. The shaded area indicates the 95% confidence interval under the 
null. In the top four panels, results are shown for the compulsive disorders (panel A), psychotic 
disorders (panel B), neurodevelopmental disorders (panel C), and internalizing disorders (panel 
D) factors from the correlated factors model. Panel E depicts the results from the 11 df omnibus 
meta-analysis across all 11 psychiatric indicators. Panel F depicts results for the hierarchical, 
second-order factor. Blue lines depict results for the psychiatric factors. Pink lines depict the 




Table 5. Genome-wide Multivariate GWAS Results 





Hits                
(LD with Q hits) 
LD with 
Trait Hits                
(LD with Q 
hits) 
Unique from Trait Hits      
(LD with Q hits) 
Multivariate GWAS 
Factor 1 (Compulsive) 19,108 1.209 0.973 1 (0) 1 (0) 0 (0) 
Factor 2 (Psychotic) 87,138 1.869 0.975 108 (1) 96 (1) 12 (0) 
Factor 3 (Neurodevelopmental) 55,932 1.301 1.022 9 (0) 7 (0) 2 (0) 
Factor 4 (Internalizing) 455,340 1.635 0.997 44 (0) 38 (0) 6 (0) 
Hierarchical   667,343 1.795 0.955 2 (1)  1 (0)  1 (1) 
Meta-Analysis - 2.216 0.883 184 145 (-) 39 (-) 
Heterogeneity Index (QSNP) 
Factor 1 QSNP   - 1.113 1.001 2 1 1 
Factor 2 QSNP   - 1.251 0.994 6 4 2 
Factor 3 QSNP   - 1.246 0.980 7 4 3 
Factor 4 QSNP   - 1.142 0.977 3 3 0 
Hierarchical QSNP   - 1.667   0.928 69  58   11 
Trait 








(LD with Q hits) 
LD with 
Factor Hits               
(LD with Q 
hits) 
Unique from Factor Hits   
(LD with Q hits) 
AN 34,467 (72,517) 1.297 1.020 8 (0) 1 (0) 7 (0) 
OCD 5,712 (9,725) 1.062 0.993 0 (0) 0 (0) 0 (0) 
TS 9,614 (14,307) 1.123 1.014 1 (0) 0 (0) 1 (0) 
SCZ 87,462 (130,644) 2.118 1.077 179 (2) 89 (2) 90 (0) 
BIP 35,967 (51,710) 1.396 1.020 16 (0) 9 (0) 7 (0) 
ALCH 155,697 (155,697) 1.199 0.994 6 (3) 2 (1) 4 (2) 
ADHD 46,586 (115,673) 1.221 0.969 6 (0) 3 (0) 3 (0) 
AUT 33,719 (46,351) 1.198 1.008 3 (1) 0 (0) 3 (1) 
PTSD 22,001 (38,593) 1.119 0.991 0 (0)  0 (0) 0 (0) 
MDD 498,520 (802,939) 1.957 1.024 109 (0) 43 (0) 66 (0) 




Note. Independent hits were defined using a pruning window of 250Kb and r2 < 0.1. Hits are considered in LD if their LD 
was R2>.10 or within a 250Kb window of one another. Values in parentheses indicate whether any of the hits were in LD 
with hits for factor-specific QSNP hits from the respective model. Effective sample size (N) was estimated using the procedure 
















From the correlated factors model, we identified 1 hit for the compulsive disorders factor 
that was also a hit for AN, and two hits for factor specific QSNP. We identified 108 hits for the 
psychotic disorders factor, 96 of which were in LD with hits from BIP and SCZ, and 12 that 
were novel relative to the univariate traits. Of these 12 unique hits, 8 have been reported as hits 
in outside GWAS of psychiatric traits, 2 were novel for psychiatric traits, and 2 were entirely 
novel. Factor specific QSNP revealed 6 hits, 3 of which were in LD with hits for ALCH, including 
a locus in the well-described ADH1B gene that was identified as a QSNP hit for all four factors.  
We identified 9 hits for the neurodevelopmental disorders factor, 3 of which were in LD 
with hits for ADHD or MDD, and 2 of which were novel relative to the univariate traits. These 
two novel hits were in LD with hits previously described for outside GWAS of psychiatric traits. 
There were 7 hits for the neurodevelopmental QSNP estimate, one of which was specific to AUT 
(rs10099100). For internalizing disorders, we identified 44 independent hits, 6 of which were not 
in LD with any univariate hits. Among these 6 novel loci, 3 were identified in outside studies of 
psychiatric traits, one has been identified for smoking initiation, and two have yet to be described 
for any trait. Three loci were identified for internalizing QSNP, all three of which were in LD with 
hits for ALCH. We note that the loss of univariate MDD hits relative to the factor hits reflects a 
combination of signal specific to MDD and splitting the MDD signal across two factors. Of the 
146 hits from PGC-CDG2, none were in LD with hits for the compulsive disorders factors, 73 
hits were in LD for psychotic disorders, 5 hits for neurodevelopmental disorders, and 19 hits for 
internalizing disorders. As 6 of these overlapping hits were redundant across the factors, the 




Hierarchical results revealed only 2 hits on the second-order p-factor, both of which were 
in LD with univariate hits for MDD and SCZ, and have been described in multiple outside 
studies of psychiatric traits. The p-factor was characterized by the highest level of heterogeneity 
by far, with 69 loci identified for hierarchical QSNP, 49 of which were in LD with hits on the four 
psychiatric factors from the correlated factors model. Using the ratio of mean 2 for the factor 
summary statistics over mean 2 for factor-specific QSNP estimates we produce an overarching 
sense of homogenous relative to heterogeneous signal at the level of the factor indicators. This 
ratio lent the most support to the psychotic disorders (ratio: 1.494) and internalizing disorders 
factor (ratio: 1.432), tentative support for the compulsive disorders factor (ratio: 1.086), and the 
least support for the neurodevelopmental disorders factor (1.044) and hierarchical factor (1.076). 
For the p-factor in particular, the combination of a high heterogeneity ratio and the lack of hits 
suggests that the ability to model a transdiagnostic risk factor reflects the convergence of 
intermediary processes that lie somewhere between overarching, genome-wide covariance and 
SNP level effects.  
DISCUSSION 
High levels of genetic overlap and polygenicity across psychiatric traits necessitate 
multivariate genomic methods that can be used to test competing hypotheses about what gave 
rise to the data generating process. Genomic SEM and Stratified Genomic SEM are applied here 
to identify an overall factor structure, genetic enrichment at the level of the psychiatric factors, 
and genetic loci that are likely culprits for causes of both phenotypic divergence and 
convergence. Analyses identify two competing factor structures. One model consisted of 4 




internalizing disorders. A second model included a second-order factor that influences these four 
correlated factors. Consistent with the phenotypic literature, this model provided tentative 
evidence for a genomic p-factor, indexing transdiagnostic risk across psychiatric disorders. 
However, genome-wide estimates of genetic overlap offer limited biological insight, and may not 
hold for certain classes of genes or individual SNPs.  
In follow-up Stratified Genomic SEM models, genetic enrichment was identified for the 
psychiatric factors across 168 binary, functional annotations. These results provided tentative 
support for both the correlated and hierarchical factor model. In support of the hierarchical 
model, there were some enrichment patterns that held across all psychiatric traits, including 
enrichment of conserved regions and brain regions more generally. Enrichment within conserved 
regions (e.g., conserved primate, GERP) is generally indicative of negative selection pressure for 
covariance patterns across psychiatric traits, whereby genetic variance with negative 
consequences on evolutionary fitness in these regions is selected against. Given both the general 
nature of evolutionarily conserved annotations, and the finding that enrichment in these is also 
observed across a range of complex traits (e.g., cognitive function, anthropometric traits; 
Finucane et al., 2018; Gazal et al., 2017), enrichment in these regions likely marks disruption in 
processes important for general functioning. In line with the correlated factors model, specific 
patterns of enrichment were also observed within the four psychiatric factors, including much 
stronger enrichment for annotations that index the intersection of PI-PTV and neuronal genes for 
the psychotic disorders factor. Multivariate GWAS was then implemented to drill down even 




Multivariate GWAS results identified novel loci not present for the univariate traits, 
highlighting the potential of Genomic SEM to provide new insight into biological processes that 
could not be gleaned from the individual traits. However, the goal of Genomic SEM is not 
explicitly to boost power, but rather to identify SNPs operating through hypothesized factor 
structures. To this end, QSNP, and the ratio of mean 2 for the factor effects over QSNP mean 2, 
was used to evaluate whether SNPs tended to operate through the identified factor structure. In 
general, results lent support to pleiotropic pathways for compulsive, psychotic, and internalizing 
disorders, but not for the neurodevelopmental disorders or p-factor. These results have important 
theoretical implications for a rapidly expanding p-factor literature, suggesting that a general 
factor of psychopathology does not hold at the level of individual genetic variants.  
It is important to note that while Genomic SEM appropriately accounts for sample 
overlap across univariate GWAS in estimating statistical , it is not able to correct for case cross-
contamination, in which individuals with one disorder are inappropriately diagnosed with 
another disorder. For example, it could be that estimates of genetic overlap between bipolar 
disorder and schizophrenia are upwardly biased as individuals with schizophrenia are incorrectly 











The ability to model genetic covariance matrices estimated from GWAS summary 
statistics produced from samples with varying and unknown degrees of sample overlap 
represents a substantive addition to genomic methods. Even for those not interested in genetics, 
hypotheses about relationships between variables that are quite rare, or exclusionary of one 
another (e.g., early and late onset of the same disorder), can now be examined using publicly 
available genomic data that can be readily downloaded online. For example, research groups 
with hypotheses about the relationship between early and late onset Alzheimer’s could now run a 
multiple regression-type model that controls for the overlap in genetic signal between these two 
traits, while also examining unique relationships with outside traits (e.g., metabolic, cognitive, 
socioeconomic traits). To the best of our knowledge, such a model would not have been possible 
prior to the advent of a method like Genomic SEM.  
In addition to examining systems of relationships at the level of genome-wide genetic 
overlap, these models can be extended to specific categories of genes using Stratified Genomic 
SEM. The ability of this method to advance etiological understanding will rapidly increase as the 
collateral information used to construct these categories become increasingly specific. For 
example, until recently, only tissue- but not cell-specific gene-expression data needed to create 
partitions were available. While useful for guiding future work, tissue-specific expression panels 
are non-specific, as they contain an array of distinct cell types and fail to provide a certain level 
of reductive precision. With the advent of single-cell RNA-sequencing (scRNA-seq), combined 
with recent surveys of cells across the central nervous system (CNS; Skene et al., 2018; Ziesel et 




medications are prescribed without diagnostic specificity (e.g., SSRIs; Vaswani, Linda, & 
Ramesh, 2003), this methodological framework has the potential to identify novel intervention 
targets for particularly comorbid presentations.  
Genomic SEM and Stratified Genomic SEM can be utilized to examine an array of 
theoretical questions, but these methods were originally developed with the express purpose of 
providing greater understanding of extensive psychiatric comorbidity. To this end, these novel 
methods were used to interrogate genetic overlap across 11 psychiatric traits. As many of these 
disorders are quite rare, it is highly unlikely that a sufficiently sized phenotypic sample exists 
that includes comorbidity patterns across such a wide diagnostic spectrum. Indeed, as certain 
disorders are exclusionary of one another, it would actually be impossible to examine their 
phenotypic associations. Thus, the multivariate, genomic framework described here offers the 
first chance to interrogate the full spectrum of disorders described in the current diagnostic 
system.  
At the genome-wide level, Genomic SEM revealed four, correlated psychiatric factors 
that are best described as reflecting compulsive, psychotic, neurodevelopmental, and 
internalizing disorders. These results suggest some possible avenues of revision for future 
iterations of the DSM (APA, 2013). For example, bipolar disorder and schizophrenia are both 
highly heritable disorders that cluster together quite strongly, can display similar symptom 
presentations (e.g., psychotic features for schizophrenia; manic episodes with psychotic features 
for bipolar disorder), and, therefore, may best be considered within a single disorder class (e.g., 
psychotic and related disorders). The argument is not that genetics should be the single 




unique opportunity to examine the multivariate architecture of a wide array of disorders, and as 
such should be considered as relevant evidence for future diagnostic revisions.  
Using Stratified Genomic SEM to estimate enrichment at the level of psychiatric factors, 
we find both patterns of divergence and convergence across disorders. Across disorders, 
conserved and brain regions were generally enriched for the psychiatric factors. However, the 
intersection of PI-PTV and neuronal genes were particularly enriched for psychotic disorders, 
and there was a general trend for brain regions to be slightly more enriched for psychotic 
disorders. This lends some tentative support to consistent findings that schizophrenia is often 
found to be more consistently associated with brain-based abnormalities (Shenton, Dickey, 
Frumin, & McCarley, 2001). As the univariate GWAS become better powered, and the 
categories used to construct these functional categories become increasingly specific, the 
methods outlined here will begin to provide an even more nuanced understanding of shared and 
specific risk across disorders.  
At the most fine-grained level, multivariate GWAS was used to examine SNP-level 
effects on the psychiatric factors. Results reveal a collection of loci that were both specific to 
individual disorders (e.g., SNPs within the ADH1B gene for alcohol use disorders), and loci that 
appear to operate at the level of the psychiatric factors. This included hits that were novel 
relative to the univariate GWAS or outside studies of psychiatric traits. Interestingly, we find 
only two loci that are significant for a p-factor that captures genetic risk across the 11 included 
disorders. These results indicate that, at the very least, some of the strongest genetic signals are 
not operating through this general risk factor. One possibility is that the p-factor described in the 




symptoms, when it is phenotypically modeled for individuals within the same sample. However, 
to the extent that a disorder like schizophrenia typically causes life stress that subsequently leads 
to later onset of a disorder like depression, the depression GWAS would still pick up on some 
genetic signal that is shared with schizophrenia. That is, univariate GWAS signals might still 
pick up on effects of disorders causing disorders, yet we still find very little evidence for SNPs 
operating through the p-factor. A more reasonable explanation for this pattern of findings is that 
a genetic p-factor reflects genetic overlap for secondary, transdiagnostic risk factors that are less 
central to psychiatric etiology relative to more primary risk factors that segregate across the four, 
correlated factors identified in the present analyses. For example, it may be that dysregulation at 
the intersection of PI-PTV genes and certain neuronal genes (e.g., GABA2) is a primary risk 
factor specific to psychotic disorders, dysregulation in human promoter regions confers primary 
risk for neurodevelopmental disorders, and tuning of conserved regions is a secondary risk factor 
across disorders and complex traits more generally.  
The extent to which factor-specific and transdiagnostic genetic enrichment identified in 
the current analyses map onto measurable phenotypic risk factors (e.g., emotion dysregulation, 
sensation seeking, etc.) will be an important next step for future research. In summary, the 
current dissertation includes the development and validation of multivariate genomic methods 
that are broadly applicable to an array of human complex traits. In their application to psychiatric 
traits, a comprehensive picture begins to emerge of patterns of genetic divergence and 
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